Fixed‐ or Controlled‐Dose Mycophenolate Mofetil with Standard‐ or Reduced‐Dose Calcineurin Inhibitors: The Opticept Trial

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Transplantation

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-6143.2009.02668.xPMID 19459794
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

  2008cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2008influential reference
• The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide

  2007cited by this paper
• Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation

  2007influential reference
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2007cited by this paper
• Mycophenolate Mofetil Is Associated with Altered Expression of Chronic Renal Transplant Histology

  2007cited by this paper
• Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts

  2006cited by this paper
• Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation

  2006influential reference
• Toxicity-Sparing Protocols Using Mycophenolate Mofetil in Renal Transplantation

  2005cited by this paper
• Influence of Cyclosporine on the Serum Concentration and Biliary Excretion of Mycophenolic Acid and 7-O-Mycophenolic Acid Glucuronide

  2005cited by this paper
• The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation

  2005cited by this paper
• Malignancy after Transplantation

  2005cited by this paper
• Lower Incidence of Chronic Allograft Nephropathy at 1 Year Post‐Transplantation in Patients Treated with Mycophenolate Mofetil

  2004cited by this paper
• Withdrawal of Cyclosporine or Tacrolimus After Addition of Mycophenolate Mofetil in Patients With Chronic Allograft Nephropathy

  2004cited by this paper
• Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology

  2004cited by this paper
• The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

  2002cited by this paper
• Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus.

  2002cited by this paper
• Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1

  2002cited by this paper
• Monitoring of Mycophenolic Acid in Clinical Transplantation

  2002cited by this paper
• Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation: a Spanish multicenter study.

  2002cited by this paper
• Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy

  2001cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation : Implications for therapeutic drug monitoring

  2000cited by this paper
• Evaluation of Limited Sampling Strategies for Estimation of 12-Hour Mycophenolic Acid Area Under the Plasma Concentration–Time Curve in Adult Renal Transplant Patients

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  2000cited by this paper
• Infectious complications in renal transplant recipients.

  2000cited by this paper
• Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.

  2000cited by this paper
• Mycophenolic acid concentrations are associated with cardiac allograft rejection.

  2000cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1996cited by this paper
• PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

  1995cited by this paper
• Predicting glomerular filtration rate after kidney transplantation.

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• The Johns Hopkins Hospital.

  1991cited by this paper
• Infectious Complications in Renal Transplant Recipients

  1980cited by this paper
• Kidney

  1969cited by this paper

• Rationalized immunosuppressant dosing in kidney transplantation: Mycophenolate mofetil AUC monitoring and key updates on tacrolimus exposure.

  2026cites this paper
• Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients at high risk of delayed graft function.

  2025cites this paper
• Exposure to mycophenolic acid at standard prescribed doses in renal transplantation recipients and clinical outcomes in the early posttransplantation period

  2025cites this paper
• The Rational Basis for Personalized Treatment Using Concentration-Guided Dosing

  2025cites this paper
• Optimizing Mycophenolate Therapy in Renal Transplant Patients Using Machine Learning and Population Pharmacokinetic Modeling

  2025cites this paper
• A Multi-National Survey on Immunosuppressive Regimens and Mycophenolate Monitoring Practices after Kidney Transplantation

  2025cites this paper
• Tacrolimus Exposure is Associated with Acute Rejection in the Early Phase After Kidney Transplantation: A Joint Modeling Approach

  2025cites this paper
• A practice guideline for therapeutic drug monitoring of mycophenolic acid for solid organ transplants

  2025cites this paper
• Analytical validation and pilot clinical application of a UPLC-MS/MS method for determining intracellular mycophenolic acid and metabolites in kidney transplant recipients.

  2025cites this paper
• Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions

  2025influential citation
• Pharmacokinetics and abbreviated AUC model of enteric-coated mycophenolate sodium in early kidney transplant recipients receiving tacrolimus

  2025cites this paper
• Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions

  2024influential citation
• Limited Sampling Strategies Fail to Accurately Predict Mycophenolic Acid Area Under the Curve in Kidney Transplant Recipients and the Impact of Enterohepatic Recirculation

  2024cites this paper
• Model-informed precision dosing: State of the art and future perspectives.

  2024cites this paper
• Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients

  2024cites this paper
• A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation

  2024cites this paper
• Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist.

  2024cites this paper
• Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis

  2024cites this paper
• Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil

  2024cites this paper
• Therapeutic Drug Monitoring of Mycophenolic Acid Identifies Kidney Transplant Recipients Responsive to Two SARS-CoV-2 mRNA Vaccine Doses

  2023cites this paper
• Evaluation of a Weight-Based Mycophenolate Mofetil Dosing Protocol for Kidney Transplant Maintenance Immunosuppression

  2023cites this paper
• Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using Ex Vivo T Cell Function Assays

  2023cites this paper
• Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsy‐Proven Acute Rejection: A Study to Provide Evidence for Longer‐Term Target Ranges

  2023cites this paper
• Management of drug‐induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: A comprehensive review

  2022cites this paper
• Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation

  2022cites this paper
• Immunosuppression in the Age of Precision Medicine.

  2022cites this paper
• Two‐year outcomes of low‐exposure extended‐release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi‐center randomized controlled trial

  2022cites this paper
• Reduction in Maintenance Immunosuppression in Kidney Transplant Recipients With Stable Donor-Derived Cell-Free DNA Measurements: A Case Series.

  2022cites this paper
• Intestinal Coated Mycophenolate Sodium

  2022cites this paper
• Estimation of Mycophenolic Acid Exposure in Chinese Renal Transplant Patients by a Joint Deep Learning Model

  2022cites this paper
• Long-Term Immunosuppression Management: Opportunities and Uncertainties.

  2021cites this paper
• Kidney Transplantation Long-Term Management Challenges Long-Term Immunosuppression Management Opportunities and Uncertainties

  2021cites this paper
• Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.

  2021cites this paper
• Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients—Results From the SAILOR Study

  2021cites this paper
• Induction and maintenance immunosuppression in pediatric kidney transplantation—Advances and controversies

  2021cites this paper
• Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

  2021cites this paper
• Beyond the Biopsy: Monitoring Immune Status in Kidney Recipients.

  2021cites this paper
• Is there Enough Evidence to Support Calcineurin Inhibitor Minimization or Avoidance in Renal Transplantation?

  2020cites this paper
• Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation

  2020cites this paper
• Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation

  2020cites this paper
• THIRTY YEARS OF TACROLIMUS IN CLINICAL PRACTICE.

  2020cites this paper
• Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients

  2020cites this paper
• Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial.

  2020cites this paper
• Interindividual Variability in Lymphocyte Stimulation and Transcriptomic Response Predicts Mycophenolic Acid Sensitivity in Healthy Volunteers

  2020cites this paper
• A new model to determine Optimal Exposure to Tacrolimus and Mycophenolate Mofetil after renal transplantation

  2020cites this paper
• Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC

  2020cites this paper
• Monitoring der immunsuppressiven Therapie

  2020influential citation
• Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion

  2020cites this paper
• Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient

  2020cites this paper
• Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function

  2020cites this paper
• Long liveTCI !

  2020cites this paper
• TDM is dead. Long live TCI!

  2020cites this paper
• Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor

  2019cites this paper
• Immunosuppressive Therapy

  2019cites this paper
• Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients.

  2019cites this paper
• Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients

  2019cites this paper
• Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation

  2019cites this paper
• Azathioprine and Mycophenolates

  2019cites this paper
• Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post–Renal Transplant

  2019cites this paper
• RELATE: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients

  2019cites this paper
• Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them?

  2019cites this paper
• Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial.

  2019cites this paper
• Evaluation of Multiple Linear Regression–Based Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients

  2018cites this paper
• Outcomes of EC-MPS combined with low-dose tacrolimus in DCD kidney transplantation for high-risk DGF recipients

  2018cites this paper
• Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study

  2018cites this paper
• Pharmacodynamic principles and target concentration intervention

  2018cites this paper
• Therapeutic Drug Monitoring of Micophenolate Mofetil in Cardiac Transplant Patients by Limited Sampling Strategy: An Update

  2018cites this paper
• A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients

  2018cites this paper
• Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial

  2018cites this paper
• Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014

  2018cites this paper
• Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation

  2018cites this paper
• Kidney Transplant in Adolescents: Medical Aspects

  2018cites this paper
• Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians

  2018cites this paper
• Roux‐en‐Y gastric bypass is an effective bridge to kidney transplantation: Results from a single center

  2018cites this paper
• Contemporary Kidney Transplantation

  2018cites this paper
• Roux-en-Ygastricbypassisaneffectivebridgetokidney transplantation:Resultsfromasinglecenter IanA.Thomas1 | JeffreyJ.Gaynor2 | TamekaJoseph1 | NestorDeLaCruz-Munoz2 | JunichiroSageshima3 | WarrenKupin1 | LindaJ.Chen2 | GaetanoCiancio2 | GeorgeW.BurkeIII2 | AdelaD.Mattiazzi1 | DavidRoth1 | GiselleGuerr

  2018cites this paper
• Immunosuppression for kidney transplantation: Where are we now and where are we going?

  2017cites this paper
• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

  2017cites this paper
• Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation

  2017cites this paper
• Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience

  2017cites this paper
• Subclinical Antibody-Mediated Rejection

  2017cites this paper
• Maintenance immunosuppressants in the management of antibody-mediated renal allograft rejection: which regimen is best?

  2017cites this paper
• Interaction of Mycophenolic Acid and Pantoprazole

  2017cites this paper
• Study on the association of UGT 1 A 9 gene c . 98 T > C polymorphism and mycophenolic acid plasma levels in renal transplant patients

  2017cites this paper
• Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure

  2016cites this paper
• Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta‐Analysis

  2016cites this paper
• Low‐target tacrolimus in de novo standard risk renal transplant recipients: A single‐centre experience

  2016cites this paper
• Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.

  2016cites this paper
• Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update

  2016cites this paper
• Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients

  2016cites this paper
• Clinical Applications of Mass Spectrometric Techniques for Chemical Diagnosis and Therapeutic Drug Monitoring

  2016cites this paper
• Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring

  2016cites this paper
• Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor–Intolerant Graft Recipients of Kidneys From Extended‐Criteria Donors

  2016cites this paper
• Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation

  2016cites this paper
• Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial
.

  2016cites this paper
• Immunosuppression: Induction, Maintenance, and Steroid Avoidance Protocols

  2016influential citation
• Examining a role for histone deacetylase inhibitors asimmunosuppressants in organ transplantation

  2016cites this paper
• Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

  2015cites this paper
• What is the intrapatient variability of mycophenolic acid trough levels?

  2015cites this paper